Vericel Corporation (VCEL)
$40.30-0.79%Close
BUYRECOVERY · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.1B
- Beta
- 1.02
- P/E (TTM)
- 83.96
- Short % float
- 10.29%
- Days to cover
- 9.6
- SI change
- -5.1%
- 1W
- +0.62%
- 1M
- +1.77%
- vs SPY 1W
- +0.76%
- vs SPY 1M
- -0.74%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 55
- VALUE
- 19
- GROWTH
- 55
- GARP
- 61
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC4.1%
REV YoY-
ROE6.9%
EPS YoY-
ROA4.8%
GROSS75
OP6
NET8
[VALUATION]
P/E TTM83.96
P/E FWD52.73
SECTOR PE20.34
INDUSTRY PE13.84
P/B5.55
P/FCF-
EV/EBITDA52.33
EV/EBIT-
PEG1.44
FCF YIELD-
RISK
INT COV-
D/E25.01
ALTMAN Z-
CURR RATIO5.04
ND/EBITDA-
BETA1.02
Company news
FAQ
- What is LOPJLB’s current signal on VCEL?
- LOPJLB’s latest quantitative signal on Vericel Corporation (VCEL) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is VCEL in?
- Vericel Corporation (VCEL) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Vericel Corporation (VCEL) do?
- Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mend…